Selecta Biosciences Revenue and Competitors
Estimated Revenue & Valuation
- Selecta Biosciences's estimated annual revenue is currently $7.6M per year.
- Selecta Biosciences's estimated revenue per employee is $155,000
Employee Data
- Selecta Biosciences has 49 Employees.
- Selecta Biosciences grew their employee count by -31% last year.
Selecta Biosciences's People
| Name | Title | Email/Phone |
|---|---|---|
1 | CMO | Reveal Email/Phone |
2 | Chief People Officer | Reveal Email/Phone |
3 | VP, Quality | Reveal Email/Phone |
4 | VP, Regulatory Affairs | Reveal Email/Phone |
5 | General Counsel, Secretary | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | Sr. Director - Therapeutic Protein Design | Reveal Email/Phone |
8 | Senior Director, Financial Planning and Analysis | Reveal Email/Phone |
9 | Director, Biologics and Gene Therapy Process Development and Manufacturing | Reveal Email/Phone |
10 | Senior Director, CMC-RA | Reveal Email/Phone |
Selecta Biosciences Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Selecta Biosciences?
Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTORâ„¢ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses. With a proven ability to induce tolerance to highly immunogenic proteins, ImmTOR has the potential to amplify the efficacy of biologic therapies, including redosing of life-saving gene therapies, as well as restore the body's natural self-tolerance in autoimmune diseases. The company's first program aimed at addressing immunogenicity to AAV gene therapies is expected to enter clinical trials in early 2021 in partnership with AskBio for the treatment of methylmalonic acidemia (MMA), a rare metabolic disorder. A wholly-owned program focused on addressing IgA nephropathy driven by ImmTOR and a therapeutic enzyme is also in development among additional product candidates. Selecta recently licensed its Phase 3 clinical product candidate, SEL-212, in chronic refractory gout to Sobi.
keywords:N/A
N/A
Total Funding
49
Number of Employees
$7.6M
Revenue (est)
-31%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Selecta Biosciences News
Selecta Biosciences (NASDAQ:SELB) Downgraded by StockNews.com to Hold. Posted by admin on Apr 21st, 2022. Share on Twitter Share on Facebook Share on...
Should You Add Selecta Biosciences Inc (SELB) Stock to Your Portfolio Tuesday? Tuesday, April 12, 2022 10:09 AM | InvestorsObserver Analysts.
SELB receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator. Sentiment Score - ,bearish. Selecta Biosciences Inc has a...
Other Companies in Watertown
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $10.8M | 50 | 6% | N/A |
#2 | N/A | 51 | 21% | N/A |
#3 | $15.1M | 51 | 21% | N/A |
#4 | $13.6M | 52 | -5% | N/A |
#5 | $15.2M | 52 | 2% | N/A |